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A B S T R A C T
The objective of this study was to evaluate in vitro and in vivo drug release from in situ forming gels prepared with
poloxamer 338 (P338) and/or 407 (P407) in N-methyl-2-pyrrolidone (NMP)/water mixtures for the model
compound bedaquiline fumarate salt. The impact of total poloxamer concentration (20%–25% (w/w)), P338/
P407 ratio (100/0%–0/100% (w/w)) and NMP/water ratio (0/100%–25/75% (v/v)) on gel point temperature
(GPT) was investigated via a design of experiments (DoE), showing that GPT decreased mainly with increasing
poloxamer concentration and decreasing P338/P407 ratio, while the relation with NMP/water ratio was more
complex resulting in a flexion. Based on the DoE, four formulations with 10mg/g bedaquiline fumarate salt, a
fixed NMP/water ratio of 25/75% (v/v) and varying total poloxamer concentration and P338/P407 ratio were
selected for evaluation of gel erosion in vitro. The fastest eroding formulation had the lowest total poloxamer
concentration (20% (w/w)) and the lowest P338/P407 ratio (20.4/79.6% (w/w)), while the formulation with
the highest total poloxamer concentration (23.5% (w/w)) and highest P338/P407 ratio (100/0% (w/w)) showed
the lowest gel erosion rate. These fast and slow eroding formulations showed a similar trend for in vitro drug
release and in vivo pharmacokinetics after intramuscular (IM) injection in rats. In vivo tmax of the IM administered
poloxamer in situ forming gels was about 6 h and a short-term sustained drug release was observed in vivo in rats
up to 24 h after dosing, similar to a solution of bedaquiline fumarate salt in polyethylene glycol (PEG400)/water.
In conclusion, IM administration of the evaluated poloxamer in situ forming gels may be useful for drugs that
require a short-term sustained release, but is not able to extend drug release rates up to weeks or months.
1. Introduction
In drug development, scientists are often confronted with drugs
having a short half-life or a low oral bioavailability due to poor solu-
bility, degradation in the gastrointestinal tract or a high first pass effect,
necessitating frequent administration. Drugs may also show high peak
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plasma concentrations, leading to side effects. This results in incon-
venience for the patient and low adherence rates, especially for long-
term therapies. Long acting injectables (LAIs), such as lipophilic solu-
tions, polymeric microspheres, aqueous micro- or nanosuspensions and
in situ forming gels, could help to overcome these challenges. They can
provide drug coverage for days to months with a single administration
and can be tailored to result in release profiles avoiding side effects or
to deliver the drug to a specific target site (Kempe and Mäder, 2012).
Compared to microparticulate systems, lipophilic solutions and in situ
forming gels with dissolved drug may reduce manufacturing cost and
complexity, since particle size control is not necessary and final ster-
ilization may happen via sterile filtration.
Poloxamers are copolymers of hydrophilic ethylene oxide (EO) and
hydrophobic propylene oxide (PO), arranged in a triblock structure
EOx–POy–EOx with the chemical formula HO[CH2–CH2O]x[CH
(CH3)–CH2O]y[CH2–CH2O]xH. The polymer blocks have varying
lengths, resulting in different polymers covering a large range of li-
quids, pastes and solids (Dumortier et al., 2006; Raymond et al., 2006).
Commonly used grades include P188, P237, P338 and P407, where “P”
stands for paste, the first two digits multiplied by 100 represent the
molecular mass of the PO core and the last digit multiplied by 10
corresponds to the weight percentage of EO (Raymond et al., 2006;
Ramya Devi et al., 2013; Escobar-Chávez et al., 2006).
Poloxamers are widely used as solubilizers, emulsifiers, wetting and
dispersing agents in oral, parenteral and topical drug products
(Dumortier et al., 2006; Raymond e al., 2006; Ramya Devi et al., 2013;
Escobar-Chávez et al., 2006). In addition, they have a reversible
thermo-responsive gelling capacity when dissolved in water (Kempe
and Mäder, 2012; Dumortier et al., 2006; Raymond et al., 2006; Ramya
Devi et al., 2013; Escobar-Chávez et al., 2006). Above the critical mi-
celle temperature (CMT) and critical micelle concentration, the
polymer chains aggregate into micelles due to dehydration of the hy-
drophobic PO blocks. When temperature increases further above the gel
point temperature (GPT), the physical entanglement and packing of the
micelles results in gel formation for sufficiently concentrated polox-
amer solutions (Dumortier et al., 2006; Ramya Devi et al., 2013;
Escobar-Chávez et al., 2006). This characteristic is especially inter-
esting when formulating thermally-induced in situ forming gel systems.
At room temperature, the gelling systems are in a liquid state, while
they form a gel at body temperature, after injection (Kempe and Mäder,
2012). Several parenteral short-term sustained release formulations
have been explored using this technology. Compared to conventional
injectable solutions, delayed and/or reduced peak plasma concentra-
tions or increased half-lives were reported for poloxamer in situ forming
gels, extending drug exposures up to a few days (Kempe and Mäder,
2012; Zhang et al., 2002; Yu et al., 2014; Shi et al., 2015; Jabarian
et al., 2013; Bhardwaj and Blanchard, 1996; Zhang et al., 2015; Veyries
et al., 1999). Release of drug substance from the gel matrix happens via
gel erosion, i.e. dissolution of the polymers from the gel surface, and/or
diffusion (Anderson et al., 2001). These processes are determined by
the characteristics of the drug substance and formulation factors like
type and concentration of the gel forming polymers and the presence of
additives (e.g. co-solvents, hypromellose, carboxymethylcellulose, …)
(Kempe and Mäder, 2012; Zhang et al., 2002). After dissolution from
the in situ forming gel depot, poloxamers are cleared almost entirely by
renal excretion, with limited metabolism (Grindel, 2002).
In this research work, in vitro and in vivo drug release from in situ
forming gels prepared with poloxamer 338 (P338) and/or 407 (P407)
in N-methyl-2-pyrrolidone (NMP)/water mixtures were evaluated for
the model compound bedaquiline fumarate salt. Poloxamers were se-
lected as gel formers based on their wide use in drug products, in-
cluding parenterals, their low cost, high water solubility, low toxicity
and known thermogelling behaviour (Kempe and Mäder, 2012;
Dumortier et al., 2006; Raymond et al., 2006; Ramya Devi et al., 2013;
Escobar-Chávez et al., 2006). NMP was added as co-solvent for its high
solubilizing capacity and water miscibility (Sanghvi et al., 2008). It is
also used as solvent in FDA approved parenteral drug products like
Eligard® and Sublocade®, which are formulated as subcutaneous in situ
forming gels with poly-(DL-lactic-co-glycolic acid) (PLGA) polymers
(Drug label 2018; Drug label information 2019). Bedaquiline fumarate
salt was chosen as model compound based on its physicochemical
characteristics. The compound is highly lipophilic (logD=5.1) and
very slightly soluble to practically insoluble in aqueous media at pH 1.5
to 13, as many drugs in development. It inhibits the proton pump of M.
tuberculosis adenosine 5′ triphosphate (ATP) synthase and is marketed
for the treatment of multi drug resistant tuberculosis (MDR-TB). The
commercial formulation is a 120.9 mg (equivalent to 100mg bedaqui-
line free base) immediate release tablet, showing peak plasma con-
centrations (Cmax) about 5 h after dosing, followed by a tri-exponential
decline in plasma concentrations with a terminal half-life of approxi-
mately 5months, likely reflecting slow release from peripheral tissues
(Summary of Product Characteristics Sirturo 100 mg tablets, 2018).
Human pharmacokinetics are dose proportional up to doses of 700mg.
The advised treatment duration for MDR-TB is 24 weeks, which makes
it interesting to explore LAIs. While bedaquiline would especially
benefit from release rates covering weeks to months, poloxamer in situ
forming gels have shown drug exposures up to a few days only, which
makes them more suitable for drugs requiring a short-term sustained
release (Kempe and Mäder, 2012; Zhang et al., 2002; Yu et al., 2014;
Shi et al., 2015; Jabarian et al., 2013; Bhardwaj and Blanchard, 1996;
Zhang et al., 2015; Veyries et al., 1999).
First, the impact of total poloxamer concentration, ratio of polox-
amer grades P338/P407 and concentration of the co-solvent NMP on
GPT of poloxamer formulations was investigated via a central compo-
site design. In a next step, the gel erosion and in vitro release were
determined for selected poloxamer formulations containing bedaquiline
fumarate salt. Finally, the pharmacokinetics of bedaquiline were eval-
uated for two in situ forming gel formulations after intramuscular (IM)
injection to the rat and compared to those of a solution in polyethylene
glycol 400 (PEG400)/water after both IM and intravenous (IV) injec-
tion.
2. Materials and methods
2.1. Materials
Bedaquiline fumarate salt and purified water originated from
Janssen Pharmaceutica NV (Beerse, Belgium). P338 and P407 were
bought from BASF (Mannheim, Germany) and PEG400 from Clariant
(Frankfurt am Main, Germany). NMP was obtained from Acros Organics
(New Jersey, USA). Water for injections was sourced from Baxter
(Lessines, Belgium) or Sterop Laboratoria (Brussels, Belgium). All other
chemicals were of reagent grade and purchased from commercial
sources.
2.2. Formulation preparations
Poloxamer placebo formulations were prepared applying the “cold
method” (Schmolka and Artificial skin, 1972). Poloxamer was added to
solvent (water or NMP/water mixtures) cooled to 5 °C. The mixture was
stored in the refrigerator and periodically stirred until a clear solution
was obtained. Poloxamer formulations containing 10mg/g bedaquiline
fumarate salt were prepared according to the same method, adding
bedaquiline fumarate salt to the poloxamer solution as a stock solution
of 100mg/mL in NMP. For the 5mg eq./mL bedaquiline fumarate salt
formulation in PEG400/water 50/50% (v/v), the drug substance was
dissolved in PEG400 and further diluted with water.
Formulations administered to rats were prepared with water for
injections and filtered through a 0.22 µm Sterivex sterile filter. For
other formulations, purified water was used.
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2.2.1. Formulations for gel point temperature design of experiments
For the GPT design of experiments (DoE), eight placebo formula-
tions were prepared as factorial points covering all combinations of a
total poloxamer concentration of 20% or 25% (w/w), a P338/P407
ratio of 0/100% or 100/0% (w/w) and a NMP/water ratio of 0/100%
or 25/75% (v/v). Six placebo formulations represented the face cen-
tered axial points with a total poloxamer concentration of 20% or 25%
(w/w), a P338/P407 ratio of 50/50% (w/w) and a NMP/water ratio of
12.5/87.5% (v/v), with a total poloxamer concentration of 22.5% (w/
w), a P338/P407 ratio of 0/100% or 100/0% (w/w) and a NMP/water
ratio of 12.5/87.5% (v/v), and with a total poloxamer concentration of
22.5% (w/w), a P338/P407 ratio of 50/50% (w/w) and a NMP/water
ratio of 0/100% or 25/75% (v/v). The center point placebo formulation
contained a total poloxamer concentration of 22.5% (w/w), a P338/
P407 ratio of 50/50% (w/w) and a NMP/water ratio of 12.5/87.5% (v/
v). The ranges applied for the DoE were based on visual gel formation
evaluations of a series of poloxamer placebo formulations.
2.2.2. Formulations for gel erosion study
Based on the GPT DoE, formulations 1, 2, 3 and 4 containing 10mg/
g bedaquiline fumarate salt were prepared in NMP/water 25/75% (v/v)
with a total poloxamer content of 23.5%, 20.0%, 20.0% or 21.9% (w/
w) and a P338/P407 ratio of 100/0%, 20.4/79.6%, 47.7/52.3% or
57.3/42.7% (w/w), respectively. The selected formulations were com-
binations of a fixed NMP/water ratio of 25/75% (v/v) to allow dis-
solution of bedaquiline fumarate salt and maximized or minimized total
poloxamer concentration and P338/P407 ratio, resulting in a GPT of
26–30 °C, a range which was based on visual gel formation evaluations.
2.2.3. Formulations for in vitro release study
Based on the gel erosion study, formulations 1 and 2 containing
10mg/g bedaquiline fumarate salt were prepared in NMP/water 25/
75% (v/v) with a total poloxamer content of 23.5% or 20.0% (w/w)
and a P338/407 ratio of 100/0% or 20.4/79.6% (w/w), respectively, as
described in Section 2.2.2.
2.2.4. Formulations for in vivo pharmacokinetic study in rats
Formulations 1 and 2 described under Section 2.2.3 and their cor-
responding placebo formulations, vehicle 1 and 2, were prepared for
the pharmacokinetic study in rats. In addition, formulation 5 of
5mg eq./mL bedaquiline fumarate salt in PEG400/water 50/50% (v/v)
was used.
2.3. In vitro evaluations
2.3.1. Gel point temperature design of experiments
The impact of NMP/water ratio (0/100%–25/75% (v/v)), total
poloxamer concentration (20%–25% (w/w)), and P338/P407 ratio (0/
100%–100/0% (w/w)) on GPT of the poloxamer placebo formulations
was investigated through a central composite design with 8 factorial
points, 6 axial points and 4 replicates of the center point. The GPT was
determined on a HAAKE rheostress rheometer (Waltham,
Massachusetts, USA) applying an oscillatory temperature-ramp mea-
surement (Peltier system) at a frequency of f= 1Hz and a temperature
increase of ΔT/t= 0.06666 °C/s. The software Design expert 10 (Stat-
Ease Inc., USA) was used to establish and analyze the design of ex-
periments. A quadratic response surface model, with 9 degrees of
freedom (model terms minus the intercept), was fitted to describe the
GPT data. Backward selection was used for model reduction purposes
based on a p-value< 0.05 for significant terms.
2.3.2. Gel erosion study
The gel erosion study was performed in duplicate for in situ forming
gel formulations 1–4. 5 g of the formulation was added to a 20mL
amber glass vial and equilibrated at 37 °C for at least 30min to allow
gel formation. Then, 1mL of 0.133M Sørensen’s phosphate buffer of pH
7.2 and 37 °C, was added to the vial to mimick muscle fluid (Juel, 2008;
Recipe Sorensen’s phosphate buffer, 2010). After time intervals of
30min (for time points up to 2 h) or 1 h (for time points from 2 to 7 h),
the buffer was removed, the vial with remaining gel was weighed and
1mL of fresh buffer was added to the vial. Gel weight loss was calcu-
lated to determine the gel erosion rate.
2.3.3. In vitro release study
The in vitro release study was performed in triplicate for in situ
forming gel formulations 1 and 2 on a Distek USP paddle apparatus 2
with 6 dissolution vessels. 2.2 g of the formulation was added to a cy-
lindric plastic cup and equilibrated at 37 °C to allow gel formation. The
cup was then transferred to a dissolution vessel containing 900mL
0.05M phosphate buffer pH 7.4 with 1% (w/v) sodium lauryl sulphate
at 37 °C and a paddle rotating at 50 rpm. Samples were collected at 5,
15, 30, 45, 60, 90, 120, 180, 240, 300, 360 and 1440min after in-
troducing the formulation into the dissolution vessel by extracting
3.5 mL of dissolution medium through a Distek needle connected to a
5mL syringe. The collected dissolution medium was filtered through a
30mm×0.2 µm Spartan Whatman filter and stored at room tempera-
ture until analysis (see Section 2.3.4). This set-up is commonly used for
in vitro release testing of drug products and represents sink conditions.
2.3.4. Analytical method for the in vitro release study
The quantification of bedaquiline in the in vitro release samples was
conducted on a Waters Acquity H-Class UHPLC system (Zellik, Belgium)
with an ultraviolet (UV) absorbance detector set at 334 nm and a
Waters Acquity CSH C18 1.7 µm 2.1×50mm column kept at 45 °C.
Sample injection volume was 3 µL. Gradient elution was applied for
3min at a flow rate of 0.6 mL/min using a mobile phase of (A) 0.1% (v/
v) trifluoroacetic acid (TFA) in water and (B) 0.05% (v/v) TFA in
acetonitrile (ACN). The percentage of (B) TFA in ACN was increased
from 10% at time zero to 90% at 1min, kept stable at 90% until
1.5 min, reduced to 10% at 2min and kept stable at 10% until 3 min.
Data were processed via Waters Empower 3 software.
2.4. In vivo pharmacokinetic study in rats
2.4.1. Animals
Pharmacokinetic evaluation was performed in Sprague Dawley rats
supplied by Charles River (Sulzfeld, Germany) with a body weight of
300 to 350 g and age of 9–11weeks at the start of the study. The rats
were group housed in polysulphon cages with corn cob bedding ma-
terial, Rodent retreat (Bio-Serv, USA) and Aspen wood block (Datesand,
UK) environmental enrichment in airconditioned (20–24 °C) rooms
with a 12 h light cycle. They were acclimatized for at least 4 days before
the study start and had free access to food and water during the entire
experimental period. All experimental procedures involving animals
were conducted following the guidelines of the Janssen Pharmaceutica
(Beerse, Belgium) Animal Ethics Committee and the local Belgium laws
controlling the use of experimental animals as well as EC Directive
2010/63/EU.
2.4.2. Pharmacokinetics
23 rats were allocated to five groups (4 animals for group 1 and 2, 6
animals for group 3 and 4 and 3 animals for group 5) based on body
weight (Table 1). In group 1 and 2, rats were dosed twice 0.363mL/kg
of vehicle 1 and 2, respectively, via intramuscular (IM) injection in the
left and right hind leg. Similar injections of formulation 1 and 2 were
administered to rats of groups 3 and 4, respectively, corresponding to a
dose of twice 3mg eq./kg. Rats of group 5 received an IV injection of
1mL/kg, or a dose of 5mg eq./kg, of formulation 5 in the vena saphena,
followed by two IM injections of 0.3 mL/kg of formulation 5 14 days
later, each delivering a dose of 1.5 mg eq./kg in the left and right hind
leg.
32 µL blood samples were collected in Vitrex micro hematocrit tubes
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“soda lime glass” with potassium ethylenediaminetetraacetic acid
(K2.EDTA) by puncture of the tail vein of the rats at specified time-
points ranging from 0.5 h to 28 days after IM dosing of groups 1 to 4
and from 0.25 to 80 h post IV and IM dosing of group 5. For groups 1 to
4, 1 rat was sacrificed at intermediate timepoints on days 1, 4 and 8
(after pharmacokinetic sampling at 2 h, 80 h and 168 h) for histological
evaluation (see Section 2.4.3). Therefore, the number of rats with
pharmacokinetic data in groups 3 and 4 was 6, 5, 4 and 3 up to time-
points of 2 h, 80 h, 168 h and 672 h, respectively. After sampling, blood
samples were immediately placed on melting ice and centrifuged at
5 °C, 1500×g for approximately 10min. Then, 10 µL plasma aliquots
were collected with Vitrex end to end pipettes in FluidX tubes and
stored in the freezer until analysis (see Section 2.4.4). Non-compart-
mental analysis was performed to calculate pharmacokinetic para-
meters using the validated computer program Phoenix™ WinNonlin®
(Certara L.P., USA). Statistical comparisons between groups were per-
formed using a two-tailed homoscedastic t-test.
2.4.3. Histology
Histological evaluation was performed for rats of groups 1 to 4. In
each group, 1 rat was evaluated at intermediate timepoints on day 1, 4
and 8 (after pharmacokinetic sampling at 2 h, 80 h and 168 h). On day
29 (after pharmacokinetic sampling at 672 h), the remaining rats were
examined, being 1 rat for groups 1 and 2 and 3 rats for groups 3 and 4.
The entire left hind leg or limb muscle group containing the IM ad-
ministration site of the rats was collected at necropsy and fixed in 10%
buffered formalin. Since the gel was colourless, a standardized sampling
of the administration site was performed. Sagittal cross sections of the
formalin-fixed administration sites were embedded in paraffin wax,
sectioned and stained with hematoxylin and eosin (H&E). All micro-
scopic slides were examined histopathologically by a board-certified
pathologist and the findings entered directly into a computerized da-
tabase (Ascentos, Pathology Data Systems Limited, Pratteln, Basel,
Switzerland).
2.4.4. Bioanalytical method for pharmacokinetics
Plasma levels of bedaquiline were determined for pharmacokinetic
samples of groups 3 to 5 using a liquid chromatography-tandem mass
spectrometry (LC-MS/MS) system consisting of a Shimadzu LC30AD
HPLC equipment with an SIL-HTC autosampler (Shimadzu Scientific
Instruments, MD, USA), coupled to an API4000™ triple quadrupole
mass spectrometer (AB Sciex, Toronto, Canada) equipped with Turbo
Ionspray source operated at 400 °C. Plasma samples were processed by
adding subsequently 20 µL milliQ water, 20 µL methanol, 20 µL internal
standard solution and 200 µL of ACN to the capillaries in the FluidX
tubes. The internal standard solution consisted of 6-deuterium labeled
bedaquiline at 100 ng/mL in methanol. After closing, the tubes were
shaken horizontally for 10min on an orbital shaker and centrifuged for
3min at 2500g. The supernatant (150 µL) was transferred to a 96-
deepwell plate and 1 µL of the sample extracts was injected onto a
Waters BEH C18 50×2.1mm, 1.7 µm column. Gradient elution was
applied for 4min at a flow rate of 0.6mL/min using a mobile phase of
(A) 0.01M ammonium formate pH 4.0 and (B) methanol. The percen-
tage of (B) methanol was increased from 65% at time zero to 85% at
1.25min, to 98% at 1.30min, kept stable at 98% until 2.49min, re-
duced to 65% at 2.50min and kept stable at 65% until 4 min. Multiple
reaction monitoring (MRM) transitions were monitored for bedaquiline
(555.2→ 58m/z) and the internal standard (561.2→ 64m/z) applying
a collision energy of 71 eV.
3. Results
3.1. In vitro evaluations
3.1.1. Gel point temperature design of experiments
The GPT determined by rheology for the 18 DoE runs defined for the
factors NMP/water ratio (factor A), total poloxamer content (factor B)
and P338/P407 ratio (factor C) is shown in Table 2.
The model equation built on significant terms is shown below:
GPT=38.3+ (1.76 * NMP/water ratio)− (0.770 * Total polox-
amer concentration)+ (0.184 * P338/P407 ratio)− (0.0715 * NMP/
water ratio * Total poloxamer concentration)+ (2.51.10−3 * NMP/
water ratio * P338/P407 ratio)− (3.94.10−3 * Total poloxamer con-
centration * P338/P407 ratio)− (0.0135 * NMP/water
ratio2)− (3.22.10−4 * P338/P407 ratio2)
GPT was significantly positively correlated with NMP/water ratio,
P338/P407 ratio, and the interaction between those two factors. GPT
was significantly negatively correlated with total poloxamer con-
centration, with the quadratic terms of NMP/water ratio and P338/
P407 ratio and with the interactions between total poloxamer con-
centration and NMP/water ratio or P338/P407 ratio.
Figs. 1A and 1B show a 3-dimensional (3D) surface plot for a P338/
P407 ratio of 50/50% (w/w) and total poloxamer concentration of
22.5% (w/w), respectively. In Fig. 1A, GPT decreased with increasing
total poloxamer concentration, as all total poloxamer concentration
terms in the DoE model equation showed a negative correlation with
GPT. Fig. 1B shows an increase in GPT with increasing P338/P407
ratio. This trend was confirmed throughout the design space and was
mainly driven by the positively correlated individual term P338/P407
ratio and its interaction with NMP/water ratio, while the interaction
with total poloxamer concentration and the quadratic term were ne-
gatively correlated with GPT. In both Figs. 1A and 1B and within the
design space, the relation between GPT and NMP/water ratio was ra-
ther complex, showing an inflection point.
3.1.2. Gel erosion study
The formulations evaluated for gel erosion with their corresponding
GPT are described in Table 3. They were selected based on the DoE
model equation described in Section 3.1.1 using Design expert 10 (Stat-
Ease Inc., USA). While fixing the NMP/water ratio of 25/75% (v/v), 4
combinations of maximized or minimized total poloxamer concentra-
tion and P338/P407 ratio were defined, resulting in a GPT of 26–30 °C.
The high NMP/water ratio was selected to allow solubility of 10mg/g
bedaquiline fumarate salt and the GPT range was defined based on
Table 1
Pharmacokinetic study design in rats.
Group N Formulation Dosing route Dose (mg eq. /kg) Dosing volume (mL/kg) Assessments
1 4 Vehicle in situ formulation 1 Intramuscular (Day 1) – 2 * 0.363 Histology: Day 1, 4, 8, 29a
2 4 Vehicle in situ formulation 2 Intramuscular (Day 1) – 2 * 0.363
3 6 In situ formulation 1 Intramuscular (Day 1) 2 * 3 2 * 0.363 Histology: Day 1, 4, 8, 29b
Pharmacokinetics: 0-672hc4 6 In situ formulation 2 Intramuscular (Day 1) 2 * 3 2 * 0.363







a For histology, 1 rat was analyzed per specified time point.
b For histology, 1 rat was analyzed on days 1, 4 and 8 and 3 rats were analyzed on day 29.
c For pharmacokinetics, 6, 5, 4 and 3 rats were analyzed for timepoints up to 2 h, 80 h, 168 h and 672 h, respectively.
S.V. Hemelryck, et al. International Journal of Pharmaceutics: X 1 (2019) 100016
4
visual gel formation tests, ensuring adequate gel formation at body
temperature.
The gel erosion, expressed as percentage weight loss (% (w/w)) as a
function of time, is shown in Fig. 2.
The slowest gel erosion rates (24–25% after 7 h) were observed for
formulation 1 with the highest total poloxamer concentration of 23.5%
(w/w) and a P338/P407 ratio of 100/0% (w/w), and formulation 4
with a total poloxamer concentration of 21.9% (w/w) and a P338/P407
ratio of 57.3/42.7% (w/w). Formulations 2 and 3 with a lower total
poloxamer concentration of 20% (w/w) eroded faster, with the fastest
gel weight loss (51% after 7 h) observed for formulation 2 with the
lower P338/P407 ratio and lower GPT as compared to formulation 3.
Up to 2 h, with buffer refreshments every 30min, the weight loss
curves were steeper than from 2 to 7 h, for which buffer refreshments
happened hourly.
Upon or after collection of the buffer samples, a precipitation was
observed in the buffer, corresponding to the Raman spectrum of be-
daquiline fumarate salt. As the experimental set-up was designed to
evaluate gel erosion rates and sink conditions for in vitro release of
bedaquiline fumarate salt were not guaranteed, quantification of be-
daquiline fumarate salt via UHPLC was not performed in the buffer
samples. Instead, an in vitro release study was executed in sink
conditions as described in Section 3.1.3.
3.1.3. In vitro release study
The in vitro release was determined for formulations 1 and 2 re-
presenting the slowest and fastest gel erosion rate, respectively, as de-
scribed in Section 3.1.2. The in vitro release profiles are shown in Fig. 3.
Formulation 1 with the slowest gel erosion rate in Section 3.1.2
corresponded to the slower in vitro release profile, while formulation 2
showed the higher gel erosion and in vitro release rate. Formulations 1
and 2 reached more than 100% in vitro release after 5 and 4 h, re-
spectively. The 107% release at the end of the profiles was in line with
the assay of the formulations, being 104%.
3.2. In vivo pharmacokinetic study in rats
3.2.1. Pharmacokinetics
In situ forming gel formulations 1 and 2, evaluated for in vitro release
in Section 3.1.3, were administered to rats via IM injection in the left
and right hind legs, corresponding to a bedaquiline fumarate salt dose
of 6mg eq./kg. In addition, PEG400 solution formulation 5 was ad-
ministered to rats via IV injection at a dose of 5mg eq./kg and via IM
injection in both hind legs delivering a dose of 3mg eq./kg. The mean
Table 2
Gel point temperature (GPT) design of experiments (DoE) responses.
Run Point Randomization Factor A: NMP/water ratio % (v/v) Factor B: total poloxamer conc % (w/w) Factor C: P338/P407 ratio % (w/w) Response: GPT °C
1 Factorial 6 0/100 20 0/100 23.28
2 Factorial 10 25/75 20 0/100 22.32
3 Factorial 12 0/100 25 0/100 18.43
4 Factorial 2 25/75 25 0/100 10.06
5 Factorial 7 0/100 20 100/0 30.03
6 Factorial 3 25/75 20 100/0 36.88
7 Factorial 4 0/100 25 100/0 24.74
8 Factorial 9 25/75 25 100/0 21.12
9 Axial 13 0/100 22.5 50/50 24.91
10 Axial 15 25/75 22.5 50/50 23.53
11 Axial 14 12.5/87.5 20 50/50 30.64
12 Axial 18 12.5/87.5 25 50/50 22.27
13 Axial 17 12.5/87.5 22.5 0/100 21.11
14 Axial 16 12.5/87.5 22.5 100/0 29.93
15 Center 11 12.5/87.5 22.5 50/50 26.37
16 Center 8 12.5/87.5 22.5 50/50 25.74
17 Center 1 12.5/87.5 22.5 50/50 26.26
18 Center 5 12.5/87.5 22.5 50/50 26.30
Fig. 1A. 3D surface plot of gel point as a function of total poloxamer concentration and NMP/water ratio at a P338/P407 ratio of 50/50% (w/w).
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pharmacokinetic profiles are shown in Fig. 4. Mean pharmacokinetic
parameters are summarized in Table 4.
After single parenteral administration of bedaquiline fumarate salt
to male rats, plasma concentrations of bedaquiline were quantifiable up
to the last sampling points, i.e. 672 h post-dose at 6mg eq./kg IM
dosing of in situ forming gel formulations 1 and 2 and 80 h post-dose at
3mg eq./kg IM and 5mg eq./kg IV dosing of PEG400 solution for-
mulation 5.
After IM dosing of the formulations 1, 2 and 5, peak concentrations
were observed around 6 h post-dose. Formulation 2 showed a sig-
nificantly higher Cmax (p value<0.001) and faster initial drop after
reaching peak concentrations (p value<0.01 for slope of logarithmic
plasma concentration-time profiles between tmax and 24 h) than for-
mulation 1, suggesting a faster drug absorption or release rate. For all
IM formulations, the slopes of the logarithmic plasma concentration-
time profiles between tmax and 24 h were significantly lower than for
formulation 5 (IV) between 6 and 24 h (p value < 0.001 for formula-
tion 1, p value < 0.01 for formulations 2 and 5 (IM)). Terminal half-
lives of formulations 1 and 2 were comparable (p value > 0.05). The
half-life calculated for formulation 5 (IM and IV) was much shorter due
to the earlier tlast and can therefore not be compared to the half-life of
formulations 1 and 2. However, logarithmic plasma concentration-time
profiles of formulations 1 and 2 (IM) declined parallel to the ones of
formulation 5 (IM and IV) between 24 and 80 h after dosing, suggesting
a similar half-life for all formulations within that timeframe. The in-
tersubject variability for pharmacokinetic parameters of formulations 1,
2 and 5 (IM) was limited and varied from 10.3 to 14.3 %CV for Cmax
(n=5 for formulations 1 and 2 and n= 3 for formulation 5) and from
2.7 to 19.5 %CV for AUClast (n= 3 for formulations 1, 2 and 5). The
intersubject variability for pharmacokinetic parameters of formulation
5 (IV) was higher and was 49.6 %CV for C0 (n= 3) and 29.9 %CV for
AUClast (n= 3).
Cmax/Dose values of formulations 1 and 5 (IM) were comparable
and lower than for formulation 2 (IM). Based on the AUC80h/Dose
values, exposures of formulations 1 and 2 (IM) were comparable and
slightly higher than for formulation 5 (IM or IV), which may (partially)
be explained by the slightly higher assay of the formulations (104% for
1 and 2 versus 98% for 5).
3.2.2. Histology
A single IM injection of in situ forming gel formulations 1 and 2 and
their corresponding vehicles to rats, resulted in minimal to slight
myofiber degeneration or necrosis, minimal to slight hemorrhage and
Fig. 1B. 3D surface plot of gel point as a function of P338/P407 ratio and NMP/water ratio at a total poloxamer concentration of 22.5% (w/w).
Table 3
Formulations for gel erosion study.
Formulation Bedaquiline fumarate salt concentration mg/g NMP/water ratio % (v/v) Total poloxamer concentration % (w/w) P338/P407 ratio % (w/w) GPT °C
1 10 25/75 23.5 100/0 26
2 10 25/75 20.0 20.4/79.6 26
3 10 25/75 20.0 47.7/52.3 30
4 10 25/75 21.9 57.3/42.7 26






















Fig. 2. Gel erosion rate in situ forming gel formulations 1–4 (individual profiles
for n=2). Red diamond: in situ forming gel formulation 1 (10 mg/g bedaqui-
line fumarate salt in 23.5% (w/w) P338 in NMP/water 25/75% (v/v)); blue
square: in situ forming gel formulation 2 (10mg/g bedaquiline fumarate salt in
20.0% (w/w) P338/P407 20.4/79.6% (w/w) in NMP/water 25/75% (v/v));
green triangle: in situ forming gel formulation 3 (10mg/g bedaquiline fumarate
salt in 20.0% (w/w) P338/P407 47.7/52.3% (w/w) in NMP/water 25/75% (v/
v)); yellow circle: in situ forming gel formulation 4 (10mg/g bedaquiline fu-
marate salt in 21.9% (w/w) P338/P407 57.3/42.7% (w/w) in NMP/water 25/
75% (v/v)).
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minimal perivascular granulocytic infiltrates in all groups on day 1. A
similar degree of myofiber degeneration or necrosis, microvacuolated
histiocytic infiltrates and chronic inflammation was noted on day 4 and
8 after dosing. The only difference between the vehicle and the for-
mulation-dosed groups was the palisading of macrophages around the
presumed gel in the formulation-dosed groups on day 8 (Fig. 5). At day
29 recovery was almost complete, only a minimal myofiber regenera-
tion, minimal histiocytic infiltrates or minimal chronic inflammation
was noted for individual rats in both vehicle- and formulation- dosed
groups.
4. Discussion
The GPT DoE investigated the impact of total poloxamer con-
centration (20%–25% (w/w)), P338/P407 ratio (0/100%–100/0% (w/
w)) and NMP/water ratio (0/100%–25/75% (v/v)) on the GPT of po-
loxamer placebo formulations. It was shown that GPT decreased with
increasing total poloxamer concentration via the negatively correlated
DoE model equation terms “total poloxamer concentration” and its
interaction with P338/407 or NMP/water ratio. This is in line with the
observations of A. Fakhari et al for P407 gels (Fakhari, 2017) and can
be explained by the fact that the polymer chains are packed more
densely at higher concentrations, lowering the energy needed to result
in dehydration and consequent gelation of the polymer chains. Within
the evaluated design space, GPT showed an increase with increasing
P338/P407 ratio, mainly driven by the positively correlated individual
term P338/P407 ratio and its interaction with NMP/water ratio, while
the interaction with total poloxamer concentration and the quadratic
term were negatively correlated with GPT. The overall positive corre-
lation is in line with the shorter polyethylene oxide (PEO) polymer
chains and lower GPT reported for poloxamer P407 (BASF and Grades,
2013; Bang, et al., 2015). The relation between GPT and NMP/water
ratio was rather complex, with positively and negatively correlated
model equation terms, showing an inflection point. A similar observa-
tion was described by Phaechamud et al. (2012). At low concentrations,
the NMP amide function undergoes mainly hydrophobic interactions,
while it interferes strongly with hydrogen bonding at higher con-
centrations (Zaichikov, 2006; Jia et al., 2014). Both interactions may
impact polymer micelle and gel formation, and lead to the complex
relation between GPT and NMP/water ratio.
Based on the GPT DoE, 4 different formulations were selected with a
GPT between 26 and 30 °C to ensure adequate gelation at body tem-
perature and a fixed NMP/water ratio of 25/75% (v/v) to allow dis-
solution of 10mg/g bedaquiline fumarate salt. Higher poloxamer con-
centrations slowed down gel erosion via an increase in number and size
of poloxamer micelles, shorter inter-micellar distance and a greater
number of cross-links between micelles, causing a greater tortuosity
and rigidity of the gel structure (Zhang et al., 2002; Bhardwaj and
Blanchard, 1996). A decreasing P338/P407 ratio led to an increased gel
erosion rate, which may be attributed to the lower molecular weight of
P407 compared to P338, requiring less time for hydration and dis-
solution of the poloxamer chains. More frequent buffer refreshments led
to steeper gel erosion curves. According to the Noyes-Whitney equation
(Smith, 2016), the poloxamer dissolution rate could be impacted by the
poloxamer concentration gradient, which would be higher for 0.5 than
1 hourly buffer refreshments.
In vitro release profiles for the in situ forming gel formulations with
lowest (formulation 1) and highest (formulation 2) gel erosion rate
followed the same rank order as the gel erosion tests, indicating that gel
erosion rate plays a significant role in the drug release. Diffusion of the
drug throughout the gel matrix cannot be ruled out, but is expected to
have a minimal effect on drug release based on available literature
(Zhang et al., 2002; Anderson et al., 2001).
Based on the gel erosion and in vitro release profiles, only a short-
term controlled release may be expected in vivo for the prepared po-
loxamer in situ forming gels. Gels eroded for 24% to 51% within 7 h and
in vitro release profiles showed 100% release within 4–5 h. Similar gel
erosion and in vitro drug release rates (about 100% after 6 h) were re-
ported by L. Zhang et al for a ceftiofur in situ forming gel formulation



















Fig. 3. In vitro release in situ forming gel formulations 1 and 2 (mean profile and
standard deviation error bars for n= 3). Red diamond: in situ forming gel
formulation 1 (10 mg/g bedaquiline fumarate salt in 23.5% (w/w) P338 in
NMP/water 25/75% (v/v)); blue square: in situ forming gel formulation 2
(10mg/g bedaquiline fumarate salt in 20.0% (w/w) P338/P407 20.4/79.6%
(w/w) in NMP/water 25/75% (v/v)).





























10000 Fig. 4. Plasma concentration-time profiles in rat
(mean profiles and standard deviation error bars for
n= 3 to 5). Red diamond: Intramuscular (IM) in situ
forming gel formulation 1 dosed at 6 mg eq./kg
(10mg/g bedaquiline fumarate salt in 23.5% (w/w)
P338 in NMP/water 25/75% (v/v)); blue square: IM
in situ forming gel formulation 2 dosed at 6 mg eq./
kg (10mg/g bedaquiline fumarate salt in 20.0% (w/
w) P338/P407 20.4/79.6% (w/w) in NMP/water
25/75% (v/v)); orange circle: IM PEG400 solution
formulation 5 dosed at 3mg eq./kg (eq. 5 mg/mL
bedaquiline fumarate salt in PEG400/water 50/50%
(v/v)); black triangle: intravenous solution for-
mulation 5 dosed at 5mg eq./kg.
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containing 25% (w/v) P407 in water (Zhang et al., 2002).
Pharmacokinetic data were in line with the gel erosion and in vitro
release tests. Both in situ forming gel formulations reached Cmax at
about 6 h and formulation 1 showed a slower release than formulation
2. The slope of the logarithmic plasma concentration-time profiles be-
tween tmax and 24 h for the in situ gel formulations was lower than the
one between 6 and 24 h for formulation 5 (IV), a solution of bedaquiline
fumarate salt in PEG400/water, indicating a short-term sustained re-
lease. However, a similar short-term release was observed for for-
mulation 5 (IM). The high viscosity of formulation 5 may have caused a
slow diffusion of the drug at the injection site.
Based on the histological evaluation of the IM administration site,
an IM injection of the bedaquiline in situ forming gels and their corre-
sponding vehicles were well tolerated, only a transient inflammatory
response was observed with almost complete recovery after 28 days.
Johnston and Miller (1985) performed a toxicological evaluation of
poloxamer vehicles after IM injection in rabbits, indicating that muscle
toxicity was proportional to the lipophilicity of the poloxamer. P407
25% (w/w) showed gross lesions and elevations in creatinine
phosphokinase comparable to normal saline and was considered an
acceptable intramuscular vehicle (Johnston and Miller, 1985). P338 is
not expected to be more toxic than P407, since it is less lipophilic.
5. Conclusions
In this study, the in vitro and in vivo drug release of in situ forming
gels containing 10mg/g bedaquiline fumarate salt, P338 and/or P407,
NMP and purified water was evaluated. Keeping the NMP/water ratio
fixed at 25/75% (v/v), the formulation with the lowest total poloxamer
concentration (20% (w/w)) and the lowest P338/P407 ratio (20.4/
79.6% (w/w)) showed the highest gel erosion rate; while the one with
the highest total poloxamer concentration (23.5% (w/w)) and highest
P338/P407 ratio (100/0% (w/w)) eroded the slowest. A similar trend
for in vitro drug release and in vivo pharmacokinetics after IM injection
in rats was observed. In vivo tmax of the poloxamer in situ forming gels
was about 6 h and a short-term sustained drug release was observed in
vivo in rats up to 24 h after dosing, similar to an IM administered so-
lution of bedaquiline fumarate salt in PEG400/water. In conclusion, IM
administration of the evaluated poloxamer in situ forming gels may be
useful for drugs that require a short-term sustained release, but is not
able to extend drug release rates up to weeks or months.
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Table 4
Pharmacokinetic parameters in rat following parenteral administration.
Analyte Bedaquiline
In situ gel Formulation 1 In situ gel Formulation 2 PEG400 solution Formulation 5
Dosing route IM IM IM IV
Dose (mg/kg) 6 6 3 5
n 5a 5a 3b 3c
C0 (ng/mL)d – – – 3589 (1779)
Cmax (ng/mL)d 237 (34) 410 (42) 94.7 (12.5) –
tmax (h)e 6 (6–8) 6 (4–6) 6 (6–6) –
tlast (h) 672 672 80 80
AUClast (ng.h/mL)d 15,588 (425) 14,295 (2274) 3238 (631) 5576 (1669)
AUC80h (ng.h/mL)d 8262 (994) 8393 (1044) 3238 (631) 5576 (1669)
AUC∞ (ng.h/mL)d 16,117 (351) 14,797 (2435) NCf 5512 (NCf)
t1/2 (h)d 158 (17.9) 164 (12.6) 48.2 (12.1) 32.1 (NCf)
C0/Dose (ng/mL)d – – – 718 (356)
Cmax/Dose (ng/mL)d 39.5 (5.63) 68.3 (7.03) 31.6 (4.15) –
AUClast/Dose (ng.h/mL)d 2598 (71) 2382 (379) 1079 (210) 1115 (334)
AUC80h/Dose (ng.h/mL)d 1377 (166) 1399 (174) 1079 (210) 1115 (334)
AUC∞/Dose (ng.h/mL)d 2686 (58.5) 2466 (406) NCf 1102 (NCf)
a n=3 for AUClast, AUC∞ and t1/2 to include only profiles up to 672 h.
b n= 0 for AUC∞ as values with R2adj < 0.90 and/or more than 20% extrapolation were omitted and n=2 for t1/2 as values with R2adj < 0.90 were omitted.
c n=1 for AUC∞ as values with R2adj < 0.90 and/or more than 20% extrapolation were omitted and n=1 for t1/2 as values with R2adj < 0.90 were omitted.
d Mean (SD).
e Median (min–max).
f NC=not calculated as n= 0 or 1.
Fig. 5. IM administration site in rat (H&E staining) – Day 8 after intramuscular
dosing in situ forming gel formulation 2 (10mg/g bedaquiline fumarate salt in
20.0% (w/w) P338/P407 20.4/79.6% (w/w) in NMP/water 25/75% (v/v)):
rim of palisading macrophages surrounding the presumed gel (clear space).
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